0.24(4.08%) Volume: 6,286,889 9:08PM EDT| Market Cap : 3.42 B | Enterprise Value : 3.42 B | P/E(TTM) : | P/B : 1.63 |
|---|
OPK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 1.01 |
OPK's Cash-to-Debt is ranked lower than
55% of the 799 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.05 vs. OPK: 1.01 ) Ranked among companies with meaningful Cash-to-Debt only. |
OPK'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 13.08 Max: No Debt Current: 1.01 |
| Equity-to-Asset | 0.76 |
OPK's Equity-to-Asset is ranked higher than
69% of the 731 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. OPK: 0.76 ) Ranked among companies with meaningful Equity-to-Asset only. |
OPK'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41 Med: 0.69 Max: 0.96 Current: 0.76 |
| Piotroski F-Score: 1 |
|
| Altman Z-Score: 3.08 |
|
| Beneish M-Score: -2.43 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -12.01 |
OPK's Operating Margin % is ranked lower than
77% of the 758 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.95 vs. OPK: -12.01 ) Ranked among companies with meaningful Operating Margin % only. |
OPK'
s Operating Margin % Range Over the Past 10 Years
Min: -31624.44 Med: -82.69 Max: -6 Current: -12.01 |
| Net Margin % | -6.52 |
OPK's Net Margin % is ranked lower than
75% of the 759 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.06 vs. OPK: -6.52 ) Ranked among companies with meaningful Net Margin % only. |
OPK'
s Net Margin % Range Over the Past 10 Years
Min: -31688.9 Med: -92.47 Max: -2.05 Current: -6.52 |
| ROE % | -3.70 |
OPK's ROE % is ranked lower than
72% of the 780 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.91 vs. OPK: -3.70 ) Ranked among companies with meaningful ROE % only. |
OPK'
s ROE % Range Over the Past 10 Years
Min: -3196.93 Med: -20.87 Max: -1.23 Current: -3.7 |
| ROA % | -2.78 |
OPK's ROA % is ranked lower than
71% of the 805 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.71 vs. OPK: -2.78 ) Ranked among companies with meaningful ROA % only. |
OPK'
s ROA % Range Over the Past 10 Years
Min: -1352.71 Med: -13.26 Max: -0.83 Current: -2.78 |
| ROC (Joel Greenblatt) % | -62.64 |
OPK's ROC (Joel Greenblatt) % is ranked lower than
79% of the 793 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 13.48 vs. OPK: -62.64 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
OPK'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93 Med: -258.52 Max: -38.15 Current: -62.64 |
| 3-Year Revenue Growth Rate | 101.30 |
OPK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 634 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.10 vs. OPK: 101.30 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
OPK'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 26 Max: 152 Current: 101.3 |
| 3-Year EPS without NRI Growth Rate | -46.30 |
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 576 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.60 vs. OPK: -46.30 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
OPK'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4 Med: -9.3 Max: 152.4 Current: -46.3 |
| George Soros 59,837 sh (New) Jim Simons 1,412,757 sh (New) John Burbank 12,234 sh (New) Joel Greenblatt 535,214 sh (+100.09%) Paul Tudor Jones 36,248 sh (+33.40%) Ken Fisher 38,229 sh (+1.07%) | Mario Gabelli 97,050 sh (unchged) | Murray Stahl 60,179 sh (-9.28%) |
| Ken Fisher 39,229 sh (+2.62%) | Jim Simons Sold Out Paul Tudor Jones Sold Out John Burbank Sold Out George Soros Sold Out Mario Gabelli 94,550 sh (-2.58%) Murray Stahl 58,149 sh (-3.37%) Joel Greenblatt 167,109 sh (-68.78%) |
| Paul Tudor Jones 93,342 sh (New) Murray Stahl 58,941 sh (+1.36%) | Mario Gabelli 94,550 sh (unchged) | Joel Greenblatt Sold Out Ken Fisher 38,979 sh (-0.64%) |
| Jim Simons 1,615,691 sh (New) Murray Stahl 61,934 sh (+5.08%) | Mario Gabelli 94,550 sh (unchged) | Paul Tudor Jones Sold Out Ken Fisher 38,229 sh (-1.92%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| Ken Fisher | 2017-06-30 | Reduce -1.92% | $6.14 - $8 | $ 6.12 | -13% | 38,229 |  | |
| Ken Fisher | 2017-03-31 | Reduce -0.64% | $7.43 - $9.38 | $ 6.12 | -27% | 38,979 | | |
| Joel Greenblatt | 2017-03-31 | Sold Out | 0.02% | $7.43 - $9.38 | $ 6.12 | -27% | 0 | |
| Joel Greenblatt | 2016-12-31 | Reduce -68.78% | 0.05% | $9.13 - $11.91 | $ 6.12 | -41% | 167,109 | |
| Mario Gabelli | 2016-12-31 | Reduce -2.58% | $9.13 - $11.91 | $ 6.12 | -41% | 94,550 | | |
| Ken Fisher | 2016-12-31 | Add 2.62% | $9.13 - $11.91 | $ 6.12 | -41% | 39,229 | | |
| George Soros | 2016-12-31 | Sold Out | 0.02% | $9.13 - $11.91 | $ 6.12 | -41% | 0 | |
| Joel Greenblatt | 2016-09-30 | Add 100.09% | 0.04% | $9.03 - $11.19 | $ 6.12 | -39% | 535,214 | |
| George Soros | 2016-09-30 | New Buy | 0.02% | $9.03 - $11.19 | $ 6.12 | -39% | 59,837 | |
| Ken Fisher | 2016-09-30 | Add 1.07% | $9.03 - $11.19 | $ 6.12 | -39% | 38,229 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!! What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:AKRX, NAS:MDCO, NYSE:CTLT, NAS:IRWD, NAS:SUPN, NAS:PAHC, NAS:RDUS, NAS:PCRX, NAS:IPXL, NAS:MNTA, NYSE:DPLO, NAS:HRTX, NAS:EGRX, NAS:FLXN, NAS:AMPH, NAS:SGYP, NYSE:LCI, NAS:SCLN, NAS:ACET, NAS:SCMP » details | |
| Traded in other countries: | XCY.Germany, OPK.Israel, OPK.Mexico, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 1.63 |
OPK's PB Ratio is ranked higher than
71% of the 751 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.80 vs. OPK: 1.63 ) Ranked among companies with meaningful PB Ratio only. |
OPK'
s PB Ratio Range Over the Past 10 Years
Min: 1.63 Med: 8.28 Max: 800 Current: 1.63 |
| PS Ratio | 2.89 |
OPK's PS Ratio is ranked higher than
50% of the 736 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.97 vs. OPK: 2.89 ) Ranked among companies with meaningful PS Ratio only. |
OPK'
s PS Ratio Range Over the Past 10 Years
Min: 2.87 Med: 31.37 Max: 158.13 Current: 2.89 |
| EV-to-EBIT | -26.51 |
OPK's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 20.11 vs. OPK: -26.51 ) Ranked among companies with meaningful EV-to-EBIT only. |
OPK'
s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8 Med: -34.25 Max: 203.7 Current: -26.51 |
| EV-to-EBITDA | -122.09 |
OPK's EV-to-EBITDA is ranked lower than
95% of the 587 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 17.50 vs. OPK: -122.09 ) Ranked among companies with meaningful EV-to-EBITDA only. |
OPK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6 Med: -34.5 Max: 539.9 Current: -122.09 |
| Current Ratio | 1.67 |
OPK's Current Ratio is ranked lower than
65% of the 782 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.40 vs. OPK: 1.67 ) Ranked among companies with meaningful Current Ratio only. |
OPK'
s Current Ratio Range Over the Past 10 Years
Min: 0.88 Med: 5.1 Max: 415 Current: 1.67 |
| Quick Ratio | 1.50 |
OPK's Quick Ratio is ranked lower than
56% of the 782 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.82 vs. OPK: 1.50 ) Ranked among companies with meaningful Quick Ratio only. |
OPK'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.68 Max: 415 Current: 1.5 |
| Days Inventory | 26.76 |
OPK's Days Inventory is ranked higher than
93% of the 707 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 117.36 vs. OPK: 26.76 ) Ranked among companies with meaningful Days Inventory only. |
OPK'
s Days Inventory Range Over the Past 10 Years
Min: 25.94 Med: 191.87 Max: 500.07 Current: 26.76 |
| Days Sales Outstanding | 77.62 |
OPK's Days Sales Outstanding is ranked higher than
54% of the 651 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 74.70 vs. OPK: 77.62 ) Ranked among companies with meaningful Days Sales Outstanding only. |
OPK'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86 Med: 153.78 Max: 727.85 Current: 77.62 |
| Days Payable | 36.43 |
OPK's Days Payable is ranked lower than
74% of the 600 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 70.96 vs. OPK: 36.43 ) Ranked among companies with meaningful Days Payable only. |
OPK'
s Days Payable Range Over the Past 10 Years
Min: 31.85 Med: 108.04 Max: 1499.3 Current: 36.43 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.60 |
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 473 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -4.10 vs. OPK: -10.60 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
OPK'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3 Med: -14.4 Max: 0.4 Current: -10.6 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Tangible-Book | 191.25 |
OPK's Price-to-Tangible-Book is ranked lower than
99% of the 690 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.51 vs. OPK: 191.25 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
OPK'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35 Med: 10.28 Max: 850 Current: 191.25 |
| Price-to-Intrinsic-Value-Projected-FCF | 2.44 | ||
| Price-to-Median-PS-Value | 0.09 |
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 712 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.09 vs. OPK: 0.09 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
OPK'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1 Med: 1.31 Max: 30 Current: 0.09 |
| Earnings Yield (Greenblatt) % | -3.77 |
OPK's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 805 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.10 vs. OPK: -3.77 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
OPK'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.7 Med: -2.8 Max: 0.5 Current: -3.77 |
| Revenue (TTM) (Mil) $ | 1,183.83 |
|---|---|
| EPS (TTM) $ | -0.16 |
| Beta | 2.16 |
| Short Percentage of Float | 21.76% |
| 52-Week Range $ | 5.85 - 12.15 |
| Shares Outstanding (Mil) | 559.40 |
| Dec17 | Dec18 | Dec19 | |
|---|---|---|---|
| Revenue (Mil $) | 1,230 | 1,370 | 1,527 |
| EPS ($) | -0.23 | -0.15 | 0.05 |
| EPS without NRI ($) | -0.23 | -0.15 | 0.05 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | 12.00% | ||
| Dividends per Share ($) | |||
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP